‘2030 Scares Me to Death’: Credit Analysts’ Urgent Warning for Healthcare CFOs
During a panel at HFMA’s annual conference, two healthcare credit analysts said the industry is already fracturing into winners and losers. And with 2030 bringing a perfect storm of demographic pressure, reimbursement cuts and AI disruption, they think window for bold action is closing fast.
Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO
Parabilis Medicines is developing a new type of peptide drug capable of hitting elusive disease targets inside cells. Cancer is the biotech’s initial focus, and the IPO cash will support lead program zolucatetide, which is in development for a rare type of tumor with limited treatment options.
Restoring the Patient-Clinician Relationship to the Center of Care
The next evolution of patient experience will not be defined by more digital touchpoints. It will be defined by giving nurses and care teams the capacity to be fully present.
From Detection to Defense: Building Fraud-Resilient Healthcare Payment Systems
Prevention requires more than faster detection. Organizations need payment programs with end-to-end visibility and controls that intervene before losses occur.
presented by
The Healthcare Payments Industry Has a Perception Problem
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.